Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JAK inhibitor
Pharma
Incyte's Opzelura scores in hidradenitis suppurativa study
The company presented positive data from a phase 2 study in mild-to-moderate hidradenitis suppurativa at the AAD's annual meeting on Sunday.
Zoey Becker
Mar 11, 2024 1:58pm
With FDA nod for Crohn's, AbbVie wins 7th indication for Rinvoq
May 18, 2023 4:25pm
Leo Pharma scores in phase 3 trial for JAK inhibitor cream
Feb 13, 2023 3:05pm
Incyte still far from eczema cream Opzelura's pricing goal
Nov 1, 2022 11:30am
EMA cracks down on JAK drugs with new limitations
Oct 28, 2022 10:20am
Incyte's Opzelura has clinched a second nod in vitiligo
Jul 19, 2022 2:11pm